Skip to content
10-Q

Quarterly Report

GINKGO BIOWORKS HOLDINGS, INC. DNA DNABW

0001628280-26-032116

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Mar 31, 2026 61.66M sh
Shares Outstanding Q1 2026 · Dec 31, 2025 58.21M sh
Capex Q1 2026 · Mar 31, 2026 $1.93M
Capex Q1 2026 · Mar 31, 2025 $7.62M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$46.69M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$51.52M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $143.86M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $167.2M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $312.42M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $561.57M
Stockholders Equity Q1 2026 · Mar 31, 2026 $443.15M
Stockholders Equity Q1 2026 · Dec 31, 2025 $508.59M
Stockholders Equity Q1 2026 · Mar 31, 2025 $647.43M
Stockholders Equity Q1 2026 · Dec 31, 2024 $716.06M
Current Liabilities Q1 2026 · Mar 31, 2026 $79.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $95.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $589.92M
Total Liabilities Q1 2026 · Dec 31, 2025 $611.11M
Current Assets Q1 2026 · Mar 31, 2026 $409.96M
Current Assets Q1 2026 · Dec 31, 2025 $471.84M
Total Assets Q1 2026 · Mar 31, 2026 $1.03B
Total Assets Q1 2026 · Dec 31, 2025 $1.12B
Eps Basic Q1 2026 · Mar 31, 2026 −$1.39
Eps Basic Q1 2026 · Mar 31, 2025 −$1.68
Sga Expense Q1 2026 · Mar 31, 2026 $37.83M
Sga Expense restated Q1 2026 · Mar 31, 2025 $39.72M
Rd Expense Q1 2026 · Mar 31, 2026 $49.92M
Rd Expense Q1 2026 · Mar 31, 2025 $70.92M
Net Income Q1 2026 · Mar 31, 2026 −$82.59M
Net Income Q1 2026 · Mar 31, 2025 −$90.96M
Operating Income Q1 2026 · Mar 31, 2026 −$71.37M
Operating Income restated Q1 2026 · Mar 31, 2025 −$80.97M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $3.1M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $4.09M
Revenue Q1 2026 · Mar 31, 2026 $19.47M
Revenue restated Q1 2026 · Mar 31, 2025 $38.23M